IP Library Granted Patent US 11,351,202
Granted Patent B2
US 11,351,202 · App. 15/849,181 · Granted Jun 7, 2022

MAPC treatment of brain injuries and diseases

Inventors: Robert Mays (Cleveland Heights, OH); Robert J. Deans (Riverside, CA); David C. Hess (Martinez, GA); James E. Carroll (Augusta, GA); Cesar V. Borlongan (Augusta, GA)
Assignees: ABT HOLDING COMPANY; AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
A61K35/50A61K31/436A61K31/4353A61K31/485A61K31/52A61K31/661A61K35/12A61K35/28A61K35/30A61K35/407A61K35/44A61K35/48A61K35/51A61K35/545A61K38/13A61K45/06C12N5/0607
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,351,202
App. No.
15/849,181
Granted
Jun 7, 2022
Kind
B2
Abstract

The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.

Claims (24)

1. A method of ameliorating a brain injury caused by hypoxia in a human subject, comprising: administering to a human subject having a brain injury caused by hypoxia mammalian multipotent adult progenitor cells characterized in that: they are not embryonic stem cells, embryonic germ cells, or germ cells, are allogeneic to the subject, express telomerase, have a normal karyotype, and have undergone at least 10-40 cell doublings in culture, wherein the subject has an immune system and wherein further the subject is not treated with immunosuppressive therapy adjunctively to administration of said cells.

2. A method according to claim 1 , wherein said progenitor cells can differentiate into cells of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.

3. A method according to claim 1 , wherein said progenitor cells are human cells.

4. A method according to claim 1 , wherein said progenitor cells are derived from cells isolated from any of placental tissue, umbilical cord tissue, umbilical cord blood, bone marrow, blood, spleen tissue, thymus tissue, spinal cord tissue, adipose tissue, and liver tissue.

5. A method according to claim 4 , wherein said progenitor cells are derived from bone marrow.

6. A method according to claim 5 , wherein said progenitor cells are derived from human bone marrow.

7. A method according to any one of claims 1 , 3 6 , wherein the brain injury is hypoxic ischemic brain injury.

8. A method according to any one of claims 1 , 3 6 , wherein the brain injury is caused by an occlusion or a blockage of blood supply.

9. A method according to any one of claims 1 , 3 6 , wherein the brain injury is a cortical infarction.

10. A method according to any one of claims 1 , 3 6 , wherein the brain injury is a stroke.

11. A method according to claim 1 , wherein said progenitor cells are administered to said subject in one or more doses comprising 10 5 to 10 8 of said cells per kilogram of the subject's mass.

12. A method according to claim 11 , wherein said progenitor cells are administered to the subject in one or more doses comprising 10 6 to 5×10 7 of said progenitor cells per kilogram of the subject's mass.

13. A method according to claim 1 , wherein in addition to said progenitor cells, one or more growth factors, differentiation factors, signaling factors, and/or factors that increase homing are administered to said subject.

14. A method according to claim 1 , wherein further any combination of one or more of each of the following is administered to said subject: an antibiotic agent, an anti-fungal agent, and/or an anti-viral agent.

15. A method according to claim 1 , wherein said progenitor cells are administered in a formulation comprising one or more other pharmaceutically active agents.

16. A method according to claim 15 , wherein said formulation further comprises any combination of one or more of: an antibiotic agent, an anti-fungal agent, and/or an anti-viral agent.

17. A method according to claim 1 , wherein said progenitor cells are administered to the subject by a parenteral route.

18. A method according to claim 17 , wherein said progenitor cells are administered by intravenous infusion.

19. A method according to claim 1 , wherein said progenitor cells are administered to the subject by stereotactic injection.

20. A method according to claim 2 , wherein said progenitor cells are derived from human bone marrow.

21. A method according to claim 20 , wherein the brain injury is hypoxic ischemic brain injury.

22. A method according to claim 20 , wherein the brain injury is caused by an occlusion or a blockage of the blood supply.

23. A method according to claim 20 , wherein the brain injury is a cortical infarction.

24. A method according to claim 20 , wherein the brain injury is a stroke.

Assignments (12)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 067606/0139 →
RELEASE OF SECURITY INTEREST Recorded May 29, 2024
From: HEALIOS K.K.
To: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
Reel/Frame 067566/0638 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 1, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 066435/0775 →
CHANGE OF NAME Recorded Mar 8, 2022
From: GEORGIA REGENTS RESEARCH INSTITUTE, INC.
To: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
Reel/Frame 059349/0464 →
CHANGE OF NAME Recorded Mar 4, 2019
From: GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTITUTE, INC.
To: GEORGIA REGENTS RESEARCH INSTITUTE, INC.
Reel/Frame 048490/0676 →
CHANGE OF NAME Recorded Mar 4, 2019
From: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.
To: GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTITUTE, INC.
Reel/Frame 048490/0615 →
CHANGE OF NAME Recorded Mar 4, 2019
From: ATHERSYS, INC.
To: ABT HOLDING COMPANY
Reel/Frame 048490/0794 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2018
From: HESS, DAVID C.; CARROLL, JAMES E.; BORLONGAN, CESAR V.
To: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.
Reel/Frame 045948/0042 →
CONFIRMATORY LICENSE Recorded Mar 29, 2018
From: MEDICAL COLLEGE OF GEORGIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045948/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2018
From: MAYS, ROBERT; DEANS, ROBERT J.
To: ATHERSYS, INC.
Reel/Frame 047226/0806 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2018
From: MAYS, ROBERT W.; DEANS, ROBERT J.
To: ATHERSYS, INC.
Reel/Frame 045766/0678 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2018
From: HESS, DAVID C.; CARROLL, JAMES E.; BORLONGAN, CESAR V.
To: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.
Reel/Frame 045768/0124 →
Continuity (4)
Continuation 12161830
Continuation In Part 11269736 · Nov 9, 2005
Provisional Application 60760951 · Jan 23, 2006
Related Publication 20180296609A1 · Oct 18, 2018